SHENZHEN

ENDURING 

Current location:​
  • Company latest research results were presented at the AACR Annual Meeting in the United States

    April 10, 2023:KYJY won the title of "Specialized & Innovative SME

    April 14, 2023:KYJYlatest research results were presented at the AACR Annual Meeting in the United States

    December 19, 2022:KYJY WON the “High-tech Enterprise Certificate”

    December 18, 2022: KYJY won the title of "Innovative Small and Medium-sized Enterprise" in Shenzhen

    November 10, 2022:Shenzhen Enduring has been on the list —— The Top 10 most growing companies of Antibody drugs ( assessed by Shanghai BioPharmaceutics Industry Association)

    May 12, 2022: "A Long Acting B Cell Depleting BiTE (Bi-Specific T Cell Engager) Significantly Ameliorated EAE Symptoms without Potential CRS Risk" (ID# 8386) will be presented as a Late Breaking Poster at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers in National Harbor, Maryland.

    While the posters may be displayed starting on Wednesday, June 1st, the official poster session will take place on Thursday, June 2nd at 5-7pm.


    Apr. 12, 2022: Bispecific ADC pipeline JY201 was presented at 2022 AACR meeting

    November 08, 2021: Dr. Wen (CSO) presented JY108 candidate at the 15th ISNI Congress (International Society of Neuroimmunology) International Conference

    September 18, 2021: Shenzhen Enduring completed the Series A financing (http://mp.weixin.qq.com/s/NmNXFs6OuPryGgm0S-x_Zg), which was led by Guozhong Capital

    July 28, 2021: Shenzhen Enduring relocated to a new address due to business expansion: B1105, Building 1, Yinxing Zhijie Phase II, No. 1301-76, Xinlan Community Sightseeing Road, Guanlan Street, Longhua District, Shenzhen

    July 20, 2021: Shenzhen Enduring's core technology platform patent was granted in the United States

    April 09, 2021: Shenzhen Enduring presented the company's pipeline JY102 at the AACR International Conference

    November 10, 2020: Shenzhen Enduring won the Top 10 Innovation Award at the 4th SATOL Life Science and Entrepreneurship Competition organized by the Chinese Academy of Engineering and Zhejiang University

    October 1, 2020: Shenzhen Enduring won the Biotechnology Excellence Award at First Zhichuang Cup competition held in Shenzhen

    September 1, 2019:Shenzhen Enduring participated in the National Innovation and Entrepreneurship Competition and won the first prize in Longhua District

    December 31, 2018: Shenzhen Enduring's Laboratory officially opened for business in Silver Star Technology Building, Longhua District, Shenzhen

    September 5, 2018: Pre-A financing completed

    July 31, 2018: Shenzhen Enduring was incorporated in Shenzhen

  • JY201 data were presented first time at AACR conference

    November 10, 2022:Shenzhen Enduring has been on the list —— The Top 10 most growing companies of Antibody drugs ( assessed by Shanghai BioPharmaceutics Industry Association)

    May 12, 2022: "A Long Acting B Cell Depleting BiTE (Bi-Specific T Cell Engager) Significantly Ameliorated EAE Symptoms without Potential CRS Risk" (ID# 8386) will be presented as a Late Breaking Poster at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers in National Harbor, Maryland.

    While the posters may be displayed starting on Wednesday, June 1st, the official poster session will take place on Thursday, June 2nd at 5-7pm.


    Apr. 12, 2022: Bispecific ADC pipeline JY201 was presented at 2022 AACR meeting

    November 08, 2021: Dr. Wen (CSO) presented JY108 candidate at the 15th ISNI Congress (International Society of Neuroimmunology) International Conference

    September 18, 2021: Shenzhen Enduring completed the Series A financing (http://mp.weixin.qq.com/s/NmNXFs6OuPryGgm0S-x_Zg), which was led by Guozhong Capital

    July 28, 2021: Shenzhen Enduring relocated to a new address due to business expansion: B1105, Building 1, Yinxing Zhijie Phase II, No. 1301-76, Xinlan Community Sightseeing Road, Guanlan Street, Longhua District, Shenzhen

    July 20, 2021: Shenzhen Enduring's core technology platform patent was granted in the United States

    April 09, 2021: Shenzhen Enduring presented the company's pipeline JY102 at the AACR International Conference

    November 10, 2020: Shenzhen Enduring won the Top 10 Innovation Award at the 4th SATOL Life Science and Entrepreneurship Competition organized by the Chinese Academy of Engineering and Zhejiang University

    October 1, 2020: Shenzhen Enduring won the Biotechnology Excellence Award at First Zhichuang Cup competition held in Shenzhen

    September 1, 2019:Shenzhen Enduring participated in the National Innovation and Entrepreneurship Competition and won the first prize in Longhua District

    December 31, 2018: Shenzhen Enduring's Laboratory officially opened for business in Silver Star Technology Building, Longhua District, Shenzhen

    September 5, 2018: Pre-A financing completed

    July 31, 2018: Shenzhen Enduring was incorporated in Shenzhen

  • Company completed Series A Financing

    Shen Zhen LTD recently announced the completion of Series A Financing. The fund raised will be used to move one PEGylated bispecific antibody into IND filing and clinical trial and build several PEGylated BsADC pipelines.

  • PEGylation Background

    Brief

  • Benefits & Perks

    Continue growth of the company relies on the quality of our employees. As an employee in Shenzhen Enduring, there are many opportunities for professional, personal, as well as financial growth. For Shenzhen Enduring to stay at the cutting edge of biologics development, we offer a comprehensive compensation package, which includes competitive salaries, generous benefits, an outstanding work environment, and excellent opportunities for professional growth. We also regularly benchmark our compensation packages against leading biotechnology companies in China to ensure that our employees enjoy the most competitive benefits possible.

    Benefit & perks
    1. Retirement insurance, health insurance, unemployment benefit, work injury compensation, maternity leave insurance, housing provident fund
    2. Holidays and paid time off
    3. Annual physical examination
    4. Team building activities
    5. Holiday gifts

  • Business Development

    Job requirements
    1. Degree: Master in science or above (double degrees with MBA preferred)
    2. Major: clinical medicine, biotechnology, pharmacy or other related field
    3. Work experience: At least five-year BD experience in drug development company and two-year plus experience of management, preferably with some investment and business transaction experience
    4. Familiar with all aspects of drug development, business cooperation, able to provide overall solutions according to company’s goal.
    5. Excellent English in reading, writing and oral presentation. Expert in literature search and in-depth market analysis
    6. Outstanding communication, organization and coordination skills, superb teamwork ability and able to travel constantly
    7. Good work ethics and ability to work under pressure

    Job Responsibilities:
    1. Participate in financing, business cooperation, business co-development and other related work
    2. Take part in R&D direction setting, product pipeline planning, project coordination, etc.
    3. Accountable for internal and external coordination of projects assigned
    4. Responsible for project investigation, report evaluation and cooperation formulation
    5. Participated in business negotiation and road show promotion
    6. Play a part in the development of company’s strategic plan and other critical initiatives.


  • Research Scientist (Chemical Analysis)

    Job Requirements:
    1. Degree: Ph.D or M.S.
    2. Major in Biology, medicine, chemistry, pharmacy or other related fields
    3. Work experience: Ph.D, 0-5 year; M.S. > 5 year
    4. The ability to design and execute various analytical methods for qualitative and quantitative analysis of proteins, antibody or ADC drugs and solve problems independently
    5. Hands-on experience with various analytical instruments, including HPLC, gas chromatography, mass spectrometry, NUCLEAR magnetic resonance, UV, INFRARED spectroscopy, etc.
    6. Experience with studies of drug stability and drug half-life under different conditions
    7. Experience in analysis of both small molecule compounds and large protein drugs preferred
    8. Experience with setting specifications and method validation required
    9. Good English in reading and writing, able to draft documents in English independently
    10. Open-minded, eager to learn with team spirit

    Job Responsibilities:
    1. Develop various analytical methods for PEGylated protein drugs
    2. Assist in the development of new technologies for the preparation and purification of protein and PEGylated derivatives, including stability analysis of raw materials, intermediates, drug products, metabolic products and etc.
    3. Draft research plans and execute experiments based on requirements of different projects. Document and analyze experiment results, draft experimental reports and present experiment results
    4. Maintain good relationship with external partners on different projects to ensure the smooth development of projects
    5. Work closely with other scientists in the company to complete assigned tasks
    6. Fulfill other duties as required


  • Research Assistant (Protein Engineering)

    Job requirements
    1. Education: bachelor degree or above
    2. Major: medicine, microbiology, biotechnology, genetic engineering
    3. Work experience: 0-5 years
    4. Experience in mammalian cell expression is preferred
    5. Knowledge of molecular biology and hands-on experience required
    6. Familiar with biomolecular testing techniques such as SDS-PAGE and Western blot

    Responsibility
    1. Engage in protein expression in mammalian cells and yeast, including but not limited to sequence optimization, vector construction, optimization of expression process, etc
    2. Carry out molecular biological experiments, including Escherichia Coli Plasmid DNA extraction, restriction enzyme digestion, protein nucleic acid electrophoresis, DNA recovery, ELISA, Western blot, etc
    3. Express recombinant proteins in yeast and CHO cell systems
    4. Screen stable cell lines and construct monoclonal cell lines
    5. Timely complete the work assigned by the supervisor, record, analyze experimental results and present the results in group meeting
    6. Draft SOP and other relevant documents

  • PEGylated Bispecific ADC Technology

    Over the past decade, ADC therapies have demonstrated much improved target selectivity and efficacy. The goal of ADC technology is solving the toxicity issue inherent in small molecule drug. Many factors contribute to the ADC’s toxicity such as random conjugation, premature release of payload, Fc related toxicity, on-target/off-tumor toxicity etc. Because of systemic toxicity, poor selectivity of biomarkers for patients, and acquired drug resistance, there is urgent need for next generation ADC technology.
    Shenzhen Enduring LTD has developed several novel PEGylated BsADCs (P-BsADC), prepared by conjugating a fusion protein of two-scFvs, which target at two different epitopes of receptors or two different receptors, with a pegylated cytotoxic payload. As expected, P-BsADCs are homogeneous without any Fc related toxicity encountered by traditional ADCs and demonstrate excellent in-vitro cytotoxicity and in-vivo inhibition of xenograft tumor. P-BsADCs are stable, showing no detectable release of the payload when incubating with human PBMC for a week at 37 oC. P-BsADCs also demonstrate efficient tumor penetration, accelerated internalization without detectable efflux, suggesting improved endosome and lysosome trafficking. In addition, P-BsADCs do not generate cytotoxicity to megakaryocyte Dam cell line as traditional ADCs do and are less toxic to the non-cancerous HaCaT cells than T-DM1 or DS-8201.

  • PEGylated Bispecific Antibody Technology

    A bispecific monoclonal antibody (BsAb) is an artificial protein that comprises antigen-binding fragments of two different monoclonal antibodies. It can bind to two different types of antigen or two different epitopes of the same antigen. The most widely application of this artificial protein is in cancer immunotherapy, where an engineered BsAb binds both to a receptor of cytotoxic cell, e.g., CD3, and a receptor of cancer cell, e.g., CD19, and redirect cytotoxic cell, e.g. T cell, to kill the cancer cells. Unfortunately, clinical researches show that T cell-based bispecific antibodies often exhibit severe cytokine storms, which limit their applications to a few clinical indications.

    The unique technology of Dual Site-specific PEGylated Bispecific Antibody (DSP-BsAb) developed by Shenzhen Enduring LTD has the characteristics of safety and high potency. The PEGylated T cell engager bispecific antibody (P-T-BsAb) developed by Shenzhen Enduring, therefore, could be especially useful to address the cytokine storms resulted from T-cell based bispecific antibody drugs while improving the selectivity of pathological target cells without touching health cells.

​ ​ Learn more